Most of the relevant data are within the manuscript and/or Supporting Information files. Data about nutritional status of a subset of our population was obtained from a third party. The data underlying the results presented in that sub-analysis are available from Action Against Hunger (ACF):<elesieur@actioncontrelafaim.org>.

Introduction {#sec007}
============

Between August 2017 and January 2018, almost 700,000 ethnic minority Rohingya fleeing violence in Myanmar arrived in Cox's Bazar District, Bangladesh. They joined approximately 200,000 Rohingya already settled in 2 registered refugee camps, Kutupalong and Nayapara, and within the Bangladeshi community \[[@pmed.1003070.ref001]\]. The new arrivals set up residence in crowded makeshift settlements around the existing camps with inadequate access to safe water, sanitation, and healthcare, which increased their vulnerability to infectious diseases. Cases of measles and diphtheria, in addition to increased diarrhea and respiratory infections, were reported during September--November 2017 \[[@pmed.1003070.ref002]\]. Although the outbreaks spilled over to the host community, unregistered recent arrivals appeared to have higher morbidity \[[@pmed.1003070.ref003]\]. To control ongoing outbreaks and prevent new ones, the Bangladesh Ministry of Health and Family Welfare and international partners conducted 7 immunization campaigns between September 2017 and April 2018, targeting different age groups with a variety of antigens \[[@pmed.1003070.ref001]\].

Trivalent oral poliovirus vaccine (tOPV, which contains serotypes 1, 2, and 3) was withdrawn from global use in April 2016 to reduce the burden of type 2 circulating vaccine-derived poliovirus (cVDPV) outbreaks \[[@pmed.1003070.ref004]\]. Following tOPV withdrawal, primary immunization against polio included 3 doses of bivalent oral poliovirus vaccine (bOPV, which contains serotypes 1 and 3) administered at 6, 10, and 14 weeks of age in Bangladesh and at 2, 4, and 6 months of age in Myanmar, plus 1 dose of inactivated poliovirus vaccine (IPV) at 14 weeks (Bangladesh) or 4 months (Myanmar) to provide protection for type 2 polio \[[@pmed.1003070.ref005]--[@pmed.1003070.ref007]\]. bOPV also became the vaccine of choice for preventative or outbreak response campaigns, whereas monovalent oral poliovirus vaccine (OPV) type 2 was restricted for use in type 2 cVDPV outbreaks \[[@pmed.1003070.ref004]\].

In Cox's Bazar, bOPV was included in 5 immunization campaigns, targeting children below 5 or 7 years of age (depending on the campaign), because of the potential risks of transmission of wild poliovirus following importation from endemic countries and the emergence of cVDPV. Outbreaks of paralytic polio caused by cVDPV usually emerge in settings with low coverage with OPV and in settings with factors that favor poliovirus transmission, such as crowding and suboptimal sanitation \[[@pmed.1003070.ref008],[@pmed.1003070.ref009]\]. Myanmar experienced cVDPV emergences in 2006--2007 (type 1, 7 cases) \[[@pmed.1003070.ref010]\], 2012 (type 1, 1 case), and 2015 (type 2, 2 cases) \[[@pmed.1003070.ref011]\], with the 2015 outbreak affecting Rohingya communities in Rakhine State. Although vaccination campaigns with tOPV were conducted in Myanmar between 2007 and 2016 to control the outbreaks, some campaigns were small and targeted only certain areas \[[@pmed.1003070.ref007]\], such that the immunity of the Rohingya children recently arrived in Cox's Bazar was uncertain.

Following the vaccination campaigns and other outbreak control measures in Cox's Bazar, the number of measles and diphtheria cases detected in the camps decreased, but transmission persisted through May 2018 \[[@pmed.1003070.ref001]\]. To evaluate remaining immunity gaps and direct future immunization activities, we conducted a cross-sectional immunity assessment and vaccination coverage survey among refugee children aged 1 to 14 years. This report presents the results for polio, and discusses lessons learned with the use of dried blood spot (DBS)--based serosurveys to support polio eradication strategies. Seroprevalence testing for other preventable diseases was done with different methodologies and with a different final sample set; those data will be presented in a related paper.

Methods {#sec008}
=======

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE Checklist](#pmed.1003070.s003){ref-type="supplementary-material"}). The methodology and analysis plan followed those described in the study protocol ([S1 Protocol](#pmed.1003070.s002){ref-type="supplementary-material"}).

Study design {#sec009}
------------

This was a cross-sectional study among children 1--14 years of age, living in makeshift settlements or in the Nayapara registered refugee camp in Cox's Bazar, Bangladesh, April 28--May 28, 2018. Children aged 1--6 years and 7--14 years were treated as independent populations because only the younger age group could have received bOPV in the recent campaigns. Polio immunity among children in the older age group (7--14 years) would depend on tOPV doses received through routine immunization or campaigns conducted in Myanmar following cVDPV outbreaks \[[@pmed.1003070.ref007]\]. The makeshift settlements and registered camp were treated as independent populations because access to health services, including immunization, was expected to be different between residents in makeshift settlements and the registered camp \[[@pmed.1003070.ref012]\].

We applied random sampling in Nayapara, where detailed household information was available, and cluster sampling in the makeshift settlements. Because the vaccination survey was conducted in coordination with an Emergency Nutrition Assessment, sampling selection and size estimations were adapted to the requirements of both surveys \[[@pmed.1003070.ref013]\]. In the Nayapara refugee camp, the United Nations High Commissioner for Refugees randomly selected 411 registered households and 113 unregistered households, with the ratio of registered to unregistered households proportional to the ratio observed in the population of the camp. The makeshift settlements were divided into blocks and further into sub-blocks (mean size 108 households, range 26--970), from which we selected 55 sub-blocks (clusters) by population proportional to size, using ENA software \[[@pmed.1003070.ref013]\]. Within each sampled cluster, surveyors enumerated all the households about 1 week before data collection, and selected 13 households by simple random sampling using a random number generator. Survey teams visited all 13 households within 1 day in the makeshift settlements, and 8 households per day in Nayapara to prevent data collectors observing Ramadan from overexertion. Within each household 1 child aged 6 months--6 years and 1 child aged 7--14 years were randomly selected, if applicable. Efforts were made to revisit absent households at least twice. There was no replacement for clusters, households, or children.

The final sample required for the nutrition survey was 715 households in the makeshift settlements (55 clusters with 13 households each) and 524 households in Nayapara. Based upon a survey conducted in November 2017 \[[@pmed.1003070.ref012]\], we estimated that 60%--65% of households would have 1 child aged 1--14 years, and non-response would be 15%--30%. Therefore, we expected to enroll 367 and 226 children aged 1--6 years in the makeshift settlements and Nayapara, respectively, and 326 children aged 7--14 years in the makeshift settlements. Assuming a design effect of 1.5 for the makeshift settlements and 1 for Nayapara, our estimated precision was ±6%--7% for a seroprevalence of 50%. Specimen collection among children aged 7--14 years could not be done in Nayapara because the survey there took place during Ramadan fasting. The Institutional Review Board of the Institute of Epidemiology, Disease Control and Research of Bangladesh had not approved specimen collection among older children during Ramadan.

Vaccination coverage survey {#sec010}
---------------------------

For each child 6 months to 14 years of age enrolled, surveyors collected demographic information (sex, age, date of arrival to the camp/settlements) and a vaccination history. Information was collected on electronic tablets using KoBoCollect software (version 1.4.8.), which allowed daily upload and remote monitoring of data quality. The questionnaire was standardized in English and Bangla languages because the Rohingya language only exists in oral form ([S1 Vaccination Questionnaire](#pmed.1003070.s004){ref-type="supplementary-material"}). Surveyors spoke Chittagonian, which is similar to Rohingya, and translated the questions during the interview, using a vocabulary agreed upon during surveyor training. Vaccination questions included whether the child had received any injectable or oral poliovirus vaccine in Myanmar or at the border upon entry, and whether the child had received vaccine in each of the 7 campaigns conducted in the camps/settlements between September 2017 and April 2018. Vaccination cards for routine immunization and campaigns were checked, and parent/caregiver recall used when vaccination cards were not available.

Most campaigns included several antigens, and we assumed that if the parent/caregiver reported that the child had received vaccine in a certain campaign, he or she would have received all the antigens recommended for that age group. During the September 2018 campaign, which delivered bOPV to children below 5 years of age and measles/rubella vaccine to children aged 9 months to 15 years, we assumed that children who were aged around 5 or 6 years received both vaccines, because age estimations were imprecise and under such conditions older children are often vaccinated in campaigns.

Specimen collection and testing {#sec011}
-------------------------------

Surveyors drew blood from children aged 1--14 years by finger prick, using a retractable safety lancet, and collected 3 or 4 drops on a Whatman 903 Protein Saver Card. DBS samples were not collected from enrolled children aged 6--11 months. Immediately after specimen collection, cards were placed on racks within a plastic box to allow for air-drying during house-to-house visits. At the end of each day, the cards were transferred to individual sealed plastic bags with desiccant gels and a humidity indicator card. Samples were stored at room temperature for up to 2 weeks, before transportation to the US Centers for Disease Control and Prevention in Atlanta. On arrival to the laboratory, the DBS samples were logged, randomized, and stored at −20°C until testing.

For testing, 3 6-mm punches (1 per serotype) were eluted to extract about 6 μl of serum per punch. Testing for neutralizing antibodies against poliovirus types 1, 2, and 3 was performed using a modified poliovirus microneutralization assay \[[@pmed.1003070.ref014]\]. Each test was run in triplicate with 2-fold serial dilutions ranging from 1:8 to 1:1,024. A neutralizing antibody titer of 1:8 has been shown to correlate with protection from poliomyelitis and was used as the threshold for seropositivity \[[@pmed.1003070.ref014]\].

Statistical analysis {#sec012}
--------------------

Demographic characteristics and vaccination history of participants with a DBS sample were summarized. Seroprevalence and 95% (Wilson) confidence limits were estimated for each serotype, age group, and camp/settlements. We evaluated the potential effect of factors such as sex, age, number of OPV doses received in recent campaigns, and receipt of any OPV in Myanmar on seroprevalence using Fisher's test or Rao--Scott chi-squared test. For a subset of children aged 1--4 years for whom nutritional status was assessed \[[@pmed.1003070.ref012],[@pmed.1003070.ref015]\], we also evaluated the potential effect of acute malnutrition (low weight for height, or wasting) or chronic malnutrition (low height for age, or stunting) using Rao--Scott chi-squared test \[[@pmed.1003070.ref015]\].

The analysis was adjusted to account for the cluster design and sampling weights in makeshift settlements. A *p*-value \< 0.05 was considered significant. Analysis were performed using SAS version 9.3 \[[@pmed.1003070.ref016]\]; R version 3.2.3 was used for the creation of graphics \[[@pmed.1003070.ref017]\].

Ethical approval {#sec013}
----------------

The survey protocol and script for verbal consent were approved by the Institutional Review Board of the Institute of Epidemiology, Disease Control and Research, of Bangladesh. The US Centers for Disease Control and Prevention considered the survey an epidemic disease control activity. Before child enrollment, surveyors explained the objectives, risks, and benefits of participation in the study to the parent/caregiver and obtained the parent/caregiver's verbal informed consent in the Rohingya language. After the parent/caregiver had provided verbal consent, surveyors conducted study procedures, although some children refused specimen collection after caregiver's consent.

Results {#sec014}
=======

Recruitment and final study sample {#sec015}
----------------------------------

The survey was conducted during April 28--May 9, 2018, in the makeshift settlements and during May 17--28, 2018, in Nayapara. As shown in [Fig 1](#pmed.1003070.g001){ref-type="fig"}, families were available during the survey visits in 94% and 92% of the houses visited in the makeshift settlements and Nayapara, respectively. All except 1 parent/caregiver accepted participating in the vaccination survey. In the makeshift settlements, DBS collection and testing were possible for 335 (83%) candidate children aged 1--6 years and 297 (78%) candidate children aged 7--14 years. In Nayapara, DBS testing results were available for 245 (87%) participants aged 1--6 years ([Fig 1](#pmed.1003070.g001){ref-type="fig"}). The most common reason for not having polio immunity data among older children in the makeshift settlements was that a DBS sample was not collected because the child was absent (66/86, 77%), and the most common reason among younger children in both areas was collection of insufficient specimen for testing (62/107, 58%).

![Sample selection among Rohingya children in Cox's Bazar, Bangladesh, April--May 2018.\
DBS, dried blood spot.](pmed.1003070.g001){#pmed.1003070.g001}

Characteristics of the population surveyed {#sec016}
------------------------------------------

The demographic characteristics and vaccination history of study participants with a DBS sample tested for poliovirus immunity showed some differences in potential access to vaccines ([Table 1](#pmed.1003070.t001){ref-type="table"}). Most children living in the makeshift settlements (89%) had arrived after August 9, 2017. In Nayapara, only 10% of children had arrived with the recent influx, and 89% of younger children were born in the camp.

10.1371/journal.pmed.1003070.t001

###### Demographic and vaccination history of Rohingya children with DBS sample available, Cox's Bazar, Bangladesh, April--May 2018.

![](pmed.1003070.t001){#pmed.1003070.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                      Makeshift settlements,\   Makeshift settlements,\   Nayapara,\                                             
                                                                      1--6 years of age         7--14 years of age        1--6 years of age                                      
  ------------------------------------------------------------------- ------------------------- ------------------------- ------------------- ----- ----- ---------- ----- ----- ----------
  Epidemiology and prior vaccination                                                                                                                                             

  Household size                                                                                335                       5 (4--7)                  297   6 (4--8)         245   6 (4--7)

  Registered refugee                                                  0                         335                       0                   0     297   0          216   245   88

  Sex male                                                            171                       335                       51                  152   297   51         133   245   54

  Arrival after August 9, 2017                                        298                       335                       89                  264   297   89         24    245   10

  Born in the camp/settlements[\*](#t001fn002){ref-type="table-fn"}   11                        329                       3                   10    290   4          217   244   89

  Received any OPV in Myanmar                                         239                       320                       75                  234   283   83         19    26    73

  Received bOPV at border                                             9                         324                       3                   14    286   5          1     28    4

  bOPV doses received in campaigns in Cox's Bazar                                                                                                                                

  Doses                                                                                         335                       4 (3--5)                  ---   ---              244   5 (4--5)

    0 doses                                                           11                        335                       3                   ---   ---   ---        4     244   2

    1--3 doses                                                        77                        335                       23                  ---   ---   ---        15    244   6

    4--5 doses                                                        247                       335                       74                  ---   ---   ---        225   244   92

  Participation in campaigns distributing bOPV in Cox's Bazar                                                                                                                    

  MR first round---September 2017                                     250                       330                       76                  198   294   67         212   240   88

  OCV second round---November 2017                                    253                       326                       78                  ---   ---   ---        219   241   91

  Penta first round---January 2018                                    274                       325                       84                  240   294   82         222   243   91

  Penta second round---February 2018                                  288                       327                       88                  253   294   86         231   242   95

  Penta third round---March 2018                                      269                       330                       82                  245   294   83         228   240   95
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

bOPV, bivalent oral poliovirus vaccine; DBS, dried blood spot; MR, measles/rubella vaccine; OCV, oral cholera vaccine; OPV, oral poliovirus vaccine; Penta, pentavalent vaccine containing diphtheria, tetanus toxoid, pertussis, *Haemophilus influenzae*, and hepatitis B antigens.

\*For children in makeshift settlements, this information was estimated from date of family arrival and reported age.

During the campaigns conducted in Cox's Bazar, 74% of younger children in the makeshift settlements and 92% of younger children in Nayapara had received \>3 bOPV doses ([Table 1](#pmed.1003070.t001){ref-type="table"}). Documentation by vaccination card was available for only 12% of doses reportedly received. Older children were not eligible for bOPV in any campaign. A high proportion of children in the makeshift settlements (75%--83%) reported having received some OPV in Myanmar, but we did not ask for the number of doses ([Table 1](#pmed.1003070.t001){ref-type="table"}). Among 40 children aged 6--11 months for whom we did not collect DBS samples, 45% had received \>3 bOPV doses during the campaigns, and 14% had received some OPV in Myanmar.

Seroprevalence and antibody titers {#sec017}
----------------------------------

Type 1 seroprevalence was 85% (95% CI 80%--89%) and 91% (95% CI 86%--95%) among the younger and older age groups in the makeshift settlements, respectively (*p =* 0.07). In Nayapara, seroprevalence among younger children was 92% (95% CI 88%--95%) ([Table 2](#pmed.1003070.t002){ref-type="table"}). Type 2 seroprevalence was lower among younger than older children living in the makeshift settlements (74% \[95% CI 68%--93%\] versus 97% \[95% CI 94%--99%\], *p \<* 0.001), and was also low among younger children in Nayapara (69% \[95% CI 63%--74%\]). Type 3 seroprevalence was below 75%, and similar for both age groups and locations. Median and interquartile range of antibody titers in seropositive children are shown on [Table 2](#pmed.1003070.t002){ref-type="table"}.

10.1371/journal.pmed.1003070.t002

###### Seroprevalence and neutralizing antibody titers to polio by camp/settlements and age group---Rohingya children, Cox's Bazar, Bangladesh, April--May 2018.

![](pmed.1003070.t002){#pmed.1003070.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                                   Makeshift settlements,\   Makeshift settlements,\   Nayapara,\                                   
                                                            1--6 years of age         7--14 years of age        1--6 years of age                            
  --------------------------------------------------------- ------------------------- ------------------------- ------------------- -------------- --------- --------------
  Polio seropositive                                                                                                                                         

  Type 1                                                    290/335                   85 (80, 89)               275/297             91 (86, 95)    225/245   92 (88, 95)

  Type 2                                                    252/335                   74 (68, 79)               285/297             97 (94, 99)    169/245   69 (63, 74)

  Type 3                                                    239/335                   72 (67, 77)               227/297             74 (68, 80)    179/245   73 (67, 78)

  Polio neutralizing antibody titers (among seropositive)                                                                                                    

  Type 1                                                    290                       90 (25, 619)              275                 60 (20, 270)   225       72 (23, 455)

  Type 2                                                    252                       101 (22, 233)             285                 50 (21, 146)   169       36 (18, 91)

  Type 3                                                    239                       48 (14, 183)              227                 32 (14, 102)   179       45 (18, 144)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data for seroprevalence are presented as percent seropositive and Wilson 95% confidence intervals. Reciprocal antibody titers are presented as median and interquartile range.

Assessment of risk factors for seroprevalence {#sec018}
---------------------------------------------

Univariate analysis found some influence of age in immunity to polio types 1 and 2. For type 1, the proportion of seropositive children in the makeshift settlements tended to be lower among children aged 1--2 years than among those aged 9--10 years (81% \[95% CI 71%--88%\] versus 97% \[95% CI 90%--99%\]), but we did not detect a significant correlation between age and seroprevalence (*p =* 0.06; [Fig 2](#pmed.1003070.g002){ref-type="fig"} and [Table 3](#pmed.1003070.t003){ref-type="table"}). Type 2 seroprevalence among children in the makeshift settlements was lowest among children aged 1--2 years (45% \[95% CI 35%--55%\]); within this age group, children aged below 2 years were born after the global switch from tOPV to bOPV in April 2016. Seroprevalence increased to 91% (95% CI 81%--96%) among children aged 3--4 years and 96% (95% CI 89%--99%) among those aged 5--6 years (*p \<* 0.001 for trend; [Table 3](#pmed.1003070.t003){ref-type="table"}). The same pattern was observed in Nayapara, where only 29% (95% CI 19%--41%) of children aged 1--2 years were seropositive to type 2 poliovirus, compared with 78% (95% CI 68%--85%) among those aged 3--4 years and 89% (95% CI 82%--94%) among those aged 5--6 years (*p \<* 0.001 for trend). Type 2 seroprevalence among children aged 7--12 years was above 90% in all age subgroups.

![Seroprevalence to poliovirus by serotype, camp/settlements, and age (2-year intervals)---Rohingya children in Cox's Bazar, Bangladesh, April--May 2018.\
Data presented as percent seropositive and Wilson 95% confidence intervals.](pmed.1003070.g002){#pmed.1003070.g002}

10.1371/journal.pmed.1003070.t003

###### Seroprevalence to poliovirus by age group, nutritional status, and vaccination history---Rohingya children, Cox's Bazar, Bangladesh, April--May 2018.

![](pmed.1003070.t003){#pmed.1003070.t003g}

  Factor                                                                                          Makeshift settlements, 1--6 years of age   Makeshift settlements, 7--14 years of age   Nayapara, 1--6 years of age                                                                      
  ----------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------- ----------------------------- -------------- ------------- ------------- ------- --------------- ---------
  **Type 1**                                                                                                                                                                                                                                                                              
  **Age (years)**                                                                                                                                                                                                                                                                         
  1--2                                                                                            98/120                                     81 (71--88)                                 0.4                           ---            ---           ---           63/66   96 (88--98)     0.3
  3--4                                                                                            122/137                                    88 (79--93)                                 ---                           ---            75/85         88 (88--98)                           
  5--6                                                                                            70/78                                      88 (79--94)                                 ---                           ---            87/94         93 (85--93)                           
  7--8                                                                                            ---                                        ---                                         ---                           106/114        95 (90--98)   0.06          ---     ---             ---
  9--10                                                                                           ---                                        ---                                         79/81                         97 (90--99)    ---           ---                                   
  11--12                                                                                          ---                                        ---                                         54/62                         85 (73--92)    ---           ---                                   
  13--14                                                                                          ---                                        ---                                         36/40                         80 (61--91)    ---           ---                                   
  **bOPV doses received in campaigns in Bangladesh**                                                                                                                                                                                                                                      
  0                                                                                               7/11                                       70 (34--91)                                 0.5                           ---            ---           ---           3/4     75 (30--95)     0.1
  1--3                                                                                            65/77                                      86 (76--93)                                 ---                           ---            13/15         87 (62--96)                           
  \>3                                                                                             218/247                                    86 (80--90)                                 ---                           ---            208/225       92 (88--95)                           
  **Received any OPV in Myanmar**                                                                                                                                                                                                                                                         
  Yes                                                                                             211/239                                    86 (80--90)                                 0.6                           220/234        93 (88--96)   0.2           19/19   100 (83--100)   0.3
  No                                                                                              66/81                                      83 (69--91)                                 42/49                         83 (67--92)    6/7           86 (49--97)                           
  **Presence of wasting (weight for height below 2 SD)**[\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                                                                           
  Yes                                                                                             19/23                                      89 (70--97)                                 0.5                           ---            ---           ---           18/19   95 (75--99)     1.0
  No                                                                                              201/234                                    84 (76--89)                                 ---                           ---            117/129       91 (84--95)                           
  **Presence of stunting (height for age below 2 SD)**[\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                                                                             
  Yes                                                                                             82/96                                      83 (71--91)                                 0.8                           ---            ---           ---           57/60   95 (86--98)     0.2
  No                                                                                              138/161                                    85 (75--92)                                 ---                           ---            78/88         89 (80--94)                           
  **Type 2**                                                                                                                                                                                                                                                                              
  **Age (years)**                                                                                                                                                                                                                                                                         
  1--2                                                                                            53/120                                     45 (35--55)                                 \<0.001                       ---            ---           ---           19/66   29 (19--41)     \<0.001
  3--4                                                                                            126/137                                    91 (81--96)                                 ---                           ---            66/85         78 (68--85)                           
  5--6                                                                                            73/78                                      96 (89--99)                                 ---                           ---            84/94         89 (82--94)                           
  7--8                                                                                            ---                                        ---                                         ---                           108/114        95 (88--98)   0.2           ---     ---             ---
  9--10                                                                                           ---                                        ---                                         81/81                         100 (---)      ---           ---                                   
  11--12                                                                                          ---                                        ---                                         60/62                         99 (92--100)   ---           ---                                   
  13--14                                                                                          ---                                        ---                                         36/40                         93 (80--98)    ---           ---                                   
  **Received any OPV in Myanmar**                                                                                                                                                                                                                                                         
  Yes                                                                                             190/239                                    79 (73--84)                                 0.003                         228/234        98 (94--99)   0.3           16/19   84 (62--94)     0.6
  No                                                                                              52/81                                      60 (48--71)                                 45/49                         94 (83--98)    5/7           71 (37--92)                           
  **Presence of wasting (weight for height below 2 SD)**[\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                                                                           
  Yes                                                                                             16/23                                      74 (53--87)                                 0.5                           ---            ---           ---           7/19    37 (19--59)     0.1
  No                                                                                              163/234                                    68 (60--74)                                 ---                           ---            75/129        58 (50--66)                           
  **Presence of stunting (height for age below 2 SD)**[\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                                                                             
  Yes                                                                                             67/96                                      67 (54--78)                                 0.9                           ---            ---           ---           37/60   62 (49--73)     0.2
  No                                                                                              112/161                                    69 (60--77)                                 ---                           ---            45/88         51 (41--61)                           
  **Type 3**                                                                                                                                                                                                                                                                              
  **Age (years)**                                                                                                                                                                                                                                                                         
  1--2                                                                                            79/120                                     68 (59--76)                                 0.5                           ---            ---           ---           50/66   76 (64--86)     0.6
  3--4                                                                                            102/137                                    75 (66--82)                                 ---                           ---            64/85         75 (65--83)                           
  5--6                                                                                            58/78                                      75 (61--85)                                 ---                           ---            65/94         69 (59--78)                           
  7--8                                                                                            ---                                        ---                                         ---                           85/114         69 (58--79)   0.06          ---     ---             ---
  9--10                                                                                           ---                                        ---                                         65/81                         81 (71--89)    ---           ---                                   
  11--12                                                                                          ---                                        ---                                         47/62                         79 (65--89)    ---           ---                                   
  13--14                                                                                          ---                                        ---                                         30/40                         69 (49--93)    ---           ---                                   
  **bOPV doses received in campaigns in Bangladesh**                                                                                                                                                                                                                                      
  0                                                                                               8/11                                       81 (52--95)                                 0.4                           ---            ---           ---           4/4     100 (51--100)   0.3
  1--3                                                                                            50/77                                      66 (54--76)                                 ---                           ---            9/15          60 (36--80)                           
  \>3                                                                                             181/247                                    74 (67--79)                                 ---                           ---            165/225       73 (67--79)                           
  **Received any OPV in Myanmar**                                                                                                                                                                                                                                                         
  Yes                                                                                             178/239                                    74 (68--80)                                 0.2                           154/197        76 (66--83)                 13/19   68 (46--85)     0.7
  No                                                                                              51/81                                      66 (55--76)                                 73/100                        72 (58--82)    4/7           57 (25--84)                           
  **Presence of wasting (weight for height below 2 SD)**[\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                                                                           
  Yes                                                                                             18/23                                      81 (61--92)                                 0.2                           ---            ---           ---           17/19   90 (69--97)     0.2
  No                                                                                              163/234                                    71 (65--76)                                 ---                           ---            94/129        73 (65--80)                           
  **Presence of stunting (height for age below 2 SD)**[\*\*](#t003fn003){ref-type="table-fn"}                                                                                                                                                                                             
  Yes                                                                                             70/96                                      76 (64--85)                                 0.4                           ---            ---           ---           42/60   70 (57--80)     0.3
  No                                                                                              111/161                                    69 (61--77)                                 ---                           ---            69/88         78 (69--86)                           

95% CIs are Wilson 95% confidence intervals of percentage.

\*Rao--Scott chi-squared test. For type 2 seroprevalence, children aged 9--12 years were aggregated to allow Rao--Scott *p-*value calculation.

\*\*Wasting or stunting was considered present when weight for height or height for age, respectively, was more than 2 SD below the mean of a standard international reference population recommended by the World Health Organization \[[@pmed.1003070.ref015]\]. Nutritional assessment was available only for a subset of children 1 to 4 years of age.

bOPV, bivalent oral poliovirus vaccine; OPV, oral poliovirus vaccine.

We did not observe higher seroprevalence for types 1 and 3 among younger children who had received more than 3 bOPV doses in the recent campaigns compared with those who had received fewer doses ([Table 3](#pmed.1003070.t003){ref-type="table"}). As mentioned above, older children, who had not received bOPV during the campaigns, had similar seropositivity and antibody titers as younger children. Receipt of any OPV in Myanmar was associated with higher type 2 seroprevalence among younger children in the makeshift settlements, as 79% (95% CI 73%--84%) of children who had received OPV in Myanmar were seropositive compared with 60% (95% CI 48%--71%) of children who had not received OPV in Myanmar (*p =* 0.003).

We did not find lower polio immunity among children 1--4 years of age who had signs of acute or chronic malnutrition ([Table 3](#pmed.1003070.t003){ref-type="table"}). Finally, there were no seroprevalence differences by sex, and seronegative children were distributed throughout the camp/settlements, without clustering in a specific area.

Discussion {#sec019}
==========

This cross-sectional assessment among Rohingya children in refugee camps and settlements in Cox's Bazar found acceptable immunity for type 1 poliovirus among children 1 to 6 years of age after receiving \>3 bOPV doses in campaigns conducted in the camps/settlements (85% seropositive in makeshift settlements and 90% in Nayapara). Type 1 seroprevalence was above 90% in children aged 7--14 years, who did not receive vaccine during the campaigns, indicating prior exposure to several OPV doses. Type 2 seroprevalence showed a significant gap in children below 2 years of age, who were born after the global switch from tOPV to bOPV use in routine immunization and campaigns, but was \>90% among older children. Finally, type 3 seroprevalence was suboptimal in both age groups and locations (below 75%).

The combination of serological assessment and coverage survey provided information on immunity gaps in specific groups that guided recommendations to the agencies that conducted the campaigns for future immunization activities. First, we were able to confirm that children 7--14 years of age, for whom immunization history was unreliable and who had not received any bOPV in campaigns after arrival to the camps/settlements, had adequate levels of immunity against all serotypes from vaccination in Myanmar. We recommended that future polio vaccination campaigns did not need to target this age group.

Second, our data suggested that children aged below 2 years in makeshift settlements likely remained under-immunized after the campaigns and should receive additional vaccination opportunities. Seroprevalence for type 1 among children aged 1--2 years was about 81% compared to 88% among children aged 3--4 years and 5--6 years. The coverage survey suggested that polio immunity would be even worse among children below 1 year of age. Only 45% of children aged 6--12 months had received \>3 bOPV doses in the campaigns, compared with 74%--92% of children aged 1--6 years. Third, the large immunity gap for type 2 poliovirus observed in children aged 1--2 years suggests that many of the children born after the April 2016 tOPV-to-bOPV global switch had not received at least 1 dose of IPV through routine immunization as recommended by WHO and country guidelines \[[@pmed.1003070.ref005]--[@pmed.1003070.ref007]\]. This observation agrees with low IPV coverage reported during 2016--2017 in both countries because of the global shortage. IPV coverage in routine immunization was 11% in 2016 and 17% in 2017 in Bangladesh, and 72% in 2016 and 12% in 2017 in Myanmar \[[@pmed.1003070.ref004],[@pmed.1003070.ref018],[@pmed.1003070.ref019]\]. Because of the low seroprevalence observed in younger children, we recommended providing catch-up doses of bOPV and at least 1 dose of IPV to children below 2 years of age, through routine immunization clinics. Addition of bOPV in future campaigns with other antigens targeting children below 5 years of age was also recommended.

Seroprevalence to types 1 and 3 among children below 7 years of age, who had received a median of 4--5 doses of bOPV recently and had been previously exposed to tOPV or bOPV, was below expectations based upon immunogenicity observed with bOPV in clinical trials. A study in India found 86% and 74% seroconversion to types 1 and 3, respectively, after 2 bOPV doses in naïve children, and a study in Bangladesh showed \>95% seroconversion to both serotypes after 3 doses \[[@pmed.1003070.ref020],[@pmed.1003070.ref021]\]. Our results suggest that bOPV delivered in campaigns may have lower immunogenicity in certain settings, and this finding will need to be confirmed with new field studies with bOPV. Studies with tOPV have shown conflicting results: Some serosurveys found higher type-specific seroprevalence with tOPV delivered exclusively during campaigns than the same number of doses administered through routine immunization \[[@pmed.1003070.ref022]\], whereas other surveys found lower immunogenicity for doses delivered through campaigns in certain populations \[[@pmed.1003070.ref023],[@pmed.1003070.ref024]\]. Factors known to interfere with the response to tOPV and bOPV, such as diarrhea and malnutrition \[[@pmed.1003070.ref025]--[@pmed.1003070.ref027]\], were prevalent in our population \[[@pmed.1003070.ref001],[@pmed.1003070.ref012]\] and may have been partially responsible for the apparent lower effectiveness of bOPV observed. Unfortunately, because of our limitations in accurately calculating the type and number of OPV doses received by each child and the small sample size of subgroups, we were unable to assess the per-dose immunogenicity of bOPV or the potential effects of factors such as malnutrition on seroprevalence \[[@pmed.1003070.ref023],[@pmed.1003070.ref027]\]. The general low reliability of polio vaccination histories to estimate population immunity has also become more relevant with the intensification of immunization campaigns in areas considered at high risk for polio outbreaks, and with the use of different serotype presentations of polio vaccines \[[@pmed.1003070.ref028]--[@pmed.1003070.ref031]\].

Polio immunity assessments using serosurveys are necessary to improve the reliability of coverage surveys but may provide insufficient information in populations at high risk. For serum-based serosurveys, skilled health staff need to collect samples by venipuncture, plus staff and equipment that are only available in certain health facilities are necessary to process and store the samples in cold chain. As a result, serosurveys are often conducted among populations visiting or near healthcare facilities, which limits our ability to capture communities whose difficult access to healthcare also makes them more likely to have been missed for immunization \[[@pmed.1003070.ref028],[@pmed.1003070.ref032],[@pmed.1003070.ref033]\].

Compared with serum samples, DBS specimens require additional manipulation and processing in the poliovirus testing laboratory, but have significant advantages for field collection. DBS specimens are easy to obtain from children and adults and do not require collection by skilled health staff. In addition, they are easier to collect and transport than venous blood specimens in remote areas and low-resource settings, because they do not require immediate centrifugation or cold chain \[[@pmed.1003070.ref028],[@pmed.1003070.ref032]\]. DBS-based serosurveys can also be coordinated with other public health activities. We combined our DBS-based serological assessment of several infectious diseases with a nutritional assessment that required blood collection by finger prick for diagnosis of anemia \[[@pmed.1003070.ref013]\]; other groups have conducted DBS serosurveys nested within Demographic and Health Surveys \[[@pmed.1003070.ref023],[@pmed.1003070.ref034]\]. Although combining surveys imposed some restrictions on our choice of sample size and number of vaccine-related questions to include in the questionnaire, savings in the time and resources required for survey implementation compensated for this drawback.

This study has several limitations. The sample was selected to be representative of the Rohingya population settled in Cox's Bazar, and the results are not generalizable to other populations. Estimation of vaccine doses was mostly based upon parent/caregiver recall of children participating in each vaccination campaign and study assumptions about children receiving bOPV during campaigns, based on the antigens delivered in that campaign and estimated child's age. Doses received during the September 2017 campaign may have been overestimated because we did not exclude children aged \>4 years who might have received measles vaccine only. The selected sample size was not sufficient to assess differences among subpopulations by age, geographical area, or risk factors. We did not conduct multivariable analysis because only age appeared to have some effect on seroprevalence in univariate analysis.

In conclusion, serological testing for polio antibodies in DBS specimens in conjunction with a coverage survey provided a robust assessment of the impact of vaccination activities conducted in Cox's Bazar, identified children that remained at risk for poliovirus transmission, and informed future vaccination activities. The use of DBS-based serosurveys enhances our ability to guide polio activities in hard-to-access communities at high risk for emergence of VDPV. However, their use must be carefully prioritized, because testing for polio antibodies in DBS specimens is resource intensive and currently can be conducted in only a small number of facilities worldwide \[[@pmed.1003070.ref035]\].
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bOPV

:   bivalent oral poliovirus vaccine

cVDPV

:   circulating vaccine-derived poliovirus

DBS

:   dried blood spot

IPV

:   inactivated poliovirus vaccine

OPV

:   oral poliovirus vaccine

tOPV

:   trivalent oral poliovirus vaccine
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